A detailed history of Allspring Global Investments Holdings, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 23,705 shares of SUPN stock, worth $875,188. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,705
Previous 34,407 31.1%
Holding current value
$875,188
Previous $920,000 19.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$25.77 - $35.16 $275,790 - $376,282
-10,702 Reduced 31.1%
23,705 $739,000
Q2 2024

Jul 26, 2024

SELL
$25.99 - $33.85 $50,160 - $65,330
-1,930 Reduced 5.31%
34,407 $920,000
Q1 2024

Apr 18, 2024

SELL
$27.11 - $35.17 $8,214 - $10,656
-303 Reduced 0.83%
36,337 $1.24 Million
Q4 2023

Jan 25, 2024

SELL
$22.72 - $29.68 $66,864 - $87,348
-2,943 Reduced 7.44%
36,640 $1.06 Million
Q3 2023

Oct 27, 2023

BUY
$27.57 - $32.91 $1.09 Million - $1.3 Million
39,583 New
39,583 $1.09 Million
Q2 2023

Jul 18, 2023

SELL
$29.91 - $38.73 $1.1 Million - $1.42 Million
-36,691 Reduced 39.94%
55,179 $1.66 Million
Q1 2023

Apr 13, 2023

BUY
$34.93 - $42.03 $1.07 Million - $1.29 Million
30,611 Added 49.97%
91,870 $3.33 Million
Q4 2022

Jan 23, 2023

BUY
$31.09 - $37.88 $1.6 Million - $1.96 Million
51,613 Added 535.07%
61,259 $2.19 Billion
Q3 2022

Oct 26, 2022

BUY
$28.79 - $35.41 $206,424 - $253,889
7,170 Added 289.58%
9,646 $326,000
Q2 2022

Jul 25, 2022

SELL
$25.33 - $34.25 $1.51 Million - $2.04 Million
-59,513 Reduced 96.01%
2,476 $71,000
Q1 2022

May 02, 2022

SELL
$28.51 - $32.9 $100,098 - $115,511
-3,511 Reduced 5.36%
61,989 $2 Million
Q4 2021

Jan 28, 2022

BUY
$26.37 - $34.22 $1.73 Million - $2.24 Million
65,500 New
65,500 $1.91 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.98B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.